<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719186</url>
  </required_header>
  <id_info>
    <org_study_id>RMN-PPCOSII</org_study_id>
    <nct_id>NCT00719186</nct_id>
  </id_info>
  <brief_title>Pregnancy in Polycystic Ovary Syndrome II</brief_title>
  <acronym>PPCOSII</acronym>
  <official_title>A 20 Week Double-Blind Randomized Trial of Clomiphene Citrate and Letrozole for the Treatment of Infertility in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary research hypothesis is that ovulation induction with an aromatase inhibitor
      (letrozole) is more likely to result in live birth than ovulation induction with a selective
      estrogen receptor modulator (clomiphene citrate) in infertile women with PCOS. A safety
      hypothesis will also be incorporated into the primary research hypothesis in which we
      hypothesize both treatments are equally safe for mother and child.

      Secondary research hypotheses include:

        1. Treatment with letrozole is more likely to result in singleton pregnancy compared to
           treatment with clomiphene citrate. Singleton pregnancy is defined as presence of a
           single intrauterine gestational sac with a single fetal pole and observable heart
           motion.

        2. Treatment with letrozole will less likely result in a first trimester intrauterine fetal
           demise than treatment with clomiphene citrate. A first trimester IUFD is defined as a
           pregnancy that ends before 13 weeks gestation.

        3. Treatment with letrozole is more likely to result in ovulation (increased ovulation
           rate) compared to treatment with clomiphene citrate. Ovulation is defined as a midluteal
           progesterone level ≥ 3 ng/mL.

        4. The shortest time to pregnancy will be with letrozole.

        5. Age, body mass index, SHBG, testosterone, LH, Anti-Mullerian Hormone (AMH), and degree
           of hirsutism and acne will be significant predictors of ovulation and conception
           regardless of treatment.

        6. Improvement in SHBG, testosterone, AMH, and LH levels will be significant predictors of
           ovulation and conception regardless of treatment.

        7. DNA polymorphisms in estrogen action genes will predict response to study drug.

        8. Quality of Life will be better on letrozole than clomiphene.

        9. Letrozole will be more cost effective at achieving singleton pregnancies than
           clomiphene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary data are promising for the use of letrozole to induce ovulation in infertile
      women with PCOS. However the true magnitude of the effect of letrozole is difficult to
      discern from prior studies. Therefore we intend to determine the safety and efficacy of
      letrozole, an aromatase inhibitor, compared to clomiphene citrate, a selective estrogen
      receptor modulator, in achieving live birth in infertile women with PCOS.

      Treatment- After progestin withdrawal, 750 women will be equally randomized to two different
      treatment arms: A) clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), or B)
      letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20
      weeks. Dose will be increased in subsequent cycles in both treatment groups for non-response
      or poor ovulatory response up to a maximum of 150 mg of clomiphene a day (x 5 days) or 7.5 mg
      of letrozole a day (x 5 days).

      Statistical Analysis- The primary analysis will use an intent-to-treat approach to examine
      differences in the live birth rate in the two treatment arms.

      Anticipated time to completion- A total of 4 years will be required to complete the study
      after start up; 31 month enrollment period, 5 month treatment period, with 9 month additional
      observation to determine pregnancy outcomes. This will be accomplished by enrolling ~3.45
      women with PCOS per center per month over the enrollment period (N = 7 RMN sites).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth</measure>
    <time_frame>as few as 5 months, up to 16 months</time_frame>
    <description>The primary outcome measure is the occurrence of a live birth during the study period. Safety measures will be the number and type of reported adverse events in subjects and offspring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Pregnancy</measure>
    <time_frame>as few as 5 months, up to 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ovulations</measure>
    <time_frame>as few as 5 months, up to 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>as few as 5 months, up to 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Complication Rate</measure>
    <time_frame>September 2008 - December 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Pregnancy</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene citrate</intervention_name>
    <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Clomid</other_name>
    <other_name>Serophene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Key Inclusion Criteria (Must have ovulatory dysfunction and either hyperandrogenism or PCO)

          1. Chronic anovulation or oligomenorrhea: defined as spontaneous intermenstrual periods
             of ≥45 days or a total of ≤8 menses per year, or for women with suspected anovulatory
             bleeding, a midluteal serum progesterone level &lt; 3 ng/mL is indicative of chronic
             anovulation. For women who have been on ovarian suppressive therapy or other
             confounding medication (i.e. insulin sensitizing agents) within the last year prior to
             the study, a history of ≤8 menses per year prior to the initiation of this prior
             therapy will qualify as evidence of oligomenorrhea. For women with more regular
             bleeding patterns, but who are suspected to be experiencing anovulatory bleeding, a
             midluteal progesterone level &lt; 3ng/mL will be evidence of ovulatory dysfunction and
             qualify as anovulation. Undiagnosed persistent vaginal bleeding should be diagnosed
             and treated prior to enrollment.

          2. Hyperandrogenism (either Hirsutism or Hyperandrogenemia) or Polycystic Ovaries on
             Ultrasound:

               1. Hirsutism is determined by a modified Ferriman-Gallwey Score &gt;8 at screening exam
                  (Hatch, Rosenfield et al. 1981 Aug 1). Subjects who have hirsutism do not need
                  local or core labs documenting elevated androgen levels.

               2. Hyperandrogenemia can be determined from local labs. Local cutoffs will be
                  pre-determined by each site prior to study initiation. Hyperandrogenemia will be
                  defined as an elevated total testosterone, or free androgen index (FAI)(in our
                  lab at Penn State College of Medicine a total T &gt; 50 ng/dL or a free androgen
                  index &gt;5) will allow entry into the study (Legro, Driscoll et al. 1998). The FAI
                  is calculated from measurable values for total T and SHBG, as previously
                  described (Miller, Rosner et al. 2004), using the following equation: (FAI =
                  Total testosterone in nmol/L / SHBG in nmol/L) X 100. Outside lab values obtained
                  within the last year documenting elevated T or FAI levels are sufficient to meet
                  criteria of hyperandrogenemia.

               3. Polycystic Ovaries on Ultrasound: We will use the revised Rotterdam criteria for
                  diagnosing polycystic ovaries (Balen, Laven et al. 2003). PCO will be defined as
                  either an ovary that contains 12 or more follicles measuring 2-9 mm in diameter,
                  or an increased ovarian volume (&gt; 10 cm3) on one ovary for entry into the study.
                  If there is a follicle &gt; 10 mm in diameter, the scan should be repeated at a time
                  of ovarian quiescence in order to calculate volume and area if the subject does
                  not otherwise qualify for the study. The presence of a single polycystic ovary
                  (PCO), either by volume or morphology, is sufficient to provide the diagnosis.

        Exclusion Criteria:

        We will exclude subjects with medical conditions that represent contraindications to CC,
        aromatase inhibitors and/or pregnancy or who are unable to comply with the study
        procedures. We will exclude subjects with poorly controlled Type I or Type II diabetes;
        undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal
        disease or abnormal serum renal function; significant anemia; history of deep venous
        thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension,
        known symptomatic heart disease; history of or suspected cervical carcinoma, endometrial
        carcinoma, or breast carcinoma; undiagnosed vaginal bleeding, and use of other medications
        known to affect reproductive function or metabolism (e.g., OCP, GnRH agonists and
        antagonists, antiandrogens, gonadotropins, anti-obesity drugs, somatostatin, diazoxide, ACE
        inhibitors, and calcium channel blockers). As in PPCOS we will allow a 2 months washout
        period for subjects who desire to participate and discontinue exclusionary medications
        (most commonly OCP, but also possibly metformin), and a period of observation or treatment
        for correctable conditions.

        Couple Inclusion Criteria

          1. Sperm concentration of 14 million/mL in at least one ejaculate within the last year,
             with at least some motile sperm.

          2. Ability to have regular intercourse during the ovulation induction phase of the study.

          3. At least one patent tube and normal uterine cavity as determined by sonohysterogram,
             hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years. An
             uncomplicated intrauterine non-IVF pregnancy and uncomplicated delivery and postpartum
             course resulting in live birth within the last three years will also serve as
             sufficient evidence of a patent tube and normal uterine cavity as long as the subject
             did not have, during the pregnancy or subsequently, risk factors for Asherman's
             syndrome or tubal disease or other disorder leading to an increased suspicion for
             intrauterine abnormality or tubal occlusion.

          4. No previous sterilization procedures (vasectomy, tubal ligation) that have been
             reversed. The prior procedure may affect study outcomes.

        Specific Exclusion Criteria

          1. Current pregnancy.

          2. Patients on oral contraceptives, depo-progestins, or hormonal implants (including
             Implanon). A two month washout period will be required prior to screening for patients
             on these agents. Longer washouts may be necessary for certain depot contraceptive
             forms or implants, especially where the implants are still in place. A one-month
             washout will be required for patients on oral cyclic progestins.

          3. Patients with hyperprolactinemia (defined as two prolactin levels at least one week
             apart &gt; 30 ng/mL or as determined by local normative values). The goal of eliminating
             patients with documented hyperprolactinemia is to decrease the heterogeneity of the
             PCOS population. These patients may be candidates for ovulation induction with
             alternate regimens (dopamine agonists). A normal level within the last year or on
             treatment is adequate for entry.

          4. Patients with known 21-hydroxylase deficiency or other enzyme deficiency leading to
             the phenotype of congenital adrenal hyperplasia. 21-hydroxylase deficiency will be
             excluded in all patients by a fasting 17-hydroxyprogesterone (17-OHP) level &lt;2 ng/mL
             (Azziz, Hincapie et al. 1999 Nov). If relevant, this level should be determined in the
             follicular phase, because the 17-hydroxyprogesterone level is likely to be elevated
             beyond this range if the patient is in the luteal phase of an infrequent ovulatory
             cycle. In the case of elevated fasting 17-OHP levels in the follicular phase, an ACTH
             stimulation test will be performed. A 1-hour stimulated value &gt; 10 ng/mL will be an
             exclusion (Moran, Knochenhauer et al. 1998). As 21-hydroxylase deficiency is a
             congenital condition, any normal level in the past of 17-hydroxyprogesterone allows
             entry into this study.

          5. Patients with menopausal levels of FSH (&gt; 15 mIU/mL). A normal level within the last
             year is adequate for entry.

          6. Patients with uncorrected thyroid disease (defined as TSH &lt; 0.2 mIU/mL or &gt;5.5
             mIU/mL). A normal level within the last year is adequate for entry.

          7. Patients diagnosed with Type I or Type II diabetes who are poorly controlled (defined
             as a glycohemoglobin level &gt; 7.0%), or patients receiving antidiabetic medications
             such as insulin, thiazolidinediones, acarbose, or sulfonylureas likely to confound the
             effects of study medication; patients currently receiving metformin XR for a diagnosis
             of Type I or Type II diabetes or for PCOS are also specifically excluded.

          8. Patients with liver disease defined as AST or ALT &gt; 2 times normal or total bilirubin
             &gt;2.5 mg/dL.

          9. Patients with renal disease defined as BUN &gt; 30 mg/dL or serum creatinine&gt; 1.4 mg/dL.

         10. Patients with significant anemia (Hemoglobin &lt; 10 g/dL).

         11. Patients with a history of deep venous thrombosis, pulmonary embolus, or
             cerebrovascular accident.

         12. Patients with known heart disease that is likely to be exacerbated by pregnancy.

         13. Patients with a history of, or suspected cervical carcinoma, endometrial carcinoma, or
             breast carcinoma. A normal Pap smear result within ACOG guidelines for Pap smear
             frequency will be required for women 21 and over.

         14. Patients with a current history of alcohol abuse. Alcohol abuse is defined as &gt; 14
             drinks/week or binge drinking.

         15. Patients enrolled simultaneously into other investigative studies that require
             medications, proscribe the study medications, limit intercourse, or otherwise prevent
             compliance with the protocol. Patients who anticipate taking longer than a one month
             break during the protocol should not be enrolled.

         16. Patients taking other medications known to affect reproductive function or metabolism.
             These medications include oral contraceptives, GnRH agonists and antagonists,
             antiandrogens, gonadotropins, anti-obesity drugs, anti-diabetic drugs such as
             metformin and thiazolidinediones, somatostatin, diazoxide, ACE inhibitors, and calcium
             channel blockers. The washout period on all these medications will be two months and a
             list is found in the appendix.

         17. Patients with a suspected adrenal or ovarian tumor secreting androgens.

         18. Patients with suspected Cushing's syndrome.

         19. Couples with previous sterilization procedures (vasectomy, tubal ligation) which have
             been reversed. The prior procedure may affect study outcomes, and patients with both a
             reversed sterilization procedure and PCOS are rare enough that exclusion should not
             adversely affect recruitment.

         20. Subjects who have undergone a bariatric surgery procedure in the recent past (&lt;12
             months) and are in a period of acute weight loss or have been advised against
             pregnancy by their bariatric surgeon.

         21. Patients with untreated poorly controlled hypertension defined as a systolic blood
             pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at
             least 60 minutes apart.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Eisenberg, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nanette Santoro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Legro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennsylvania State University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Brzyski, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Casson, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Diamond, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heping Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory M Christman, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Coutifaris, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William D Schlaff, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado Denver Health Science Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-7333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University, School of Medicine</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://c2s2.yale.edu/rmn/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>May 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2014</results_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Heping Zhang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Infertility</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Clomiphene Citrate</title>
          <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Letrozole</title>
          <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="376"/>
                <participants group_id="P2" count="374"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="376"/>
                <participants group_id="P2" count="374"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Clomiphene Citrate</title>
          <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Letrozole</title>
          <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="376"/>
            <count group_id="B2" value="374"/>
            <count group_id="B3" value="750"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="4.0"/>
                    <measurement group_id="B2" value="28.9" spread="4.5"/>
                    <measurement group_id="B3" value="28.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="750"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="750"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Live Birth</title>
        <description>The primary outcome measure is the occurrence of a live birth during the study period. Safety measures will be the number and type of reported adverse events in subjects and offspring.</description>
        <time_frame>as few as 5 months, up to 16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Clomiphene Citrate</title>
            <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Letrozole</title>
            <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth</title>
          <description>The primary outcome measure is the occurrence of a live birth during the study period. Safety measures will be the number and type of reported adverse events in subjects and offspring.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pregnancy</title>
        <time_frame>as few as 5 months, up to 16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Clomiphene Citrate</title>
            <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Letrozole</title>
            <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pregnancy</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ovulations</title>
        <time_frame>as few as 5 months, up to 16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Clomiphene Citrate</title>
            <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Letrozole</title>
            <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ovulations</title>
          <units>ovulations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331"/>
                    <measurement group_id="O2" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Adverse Events</title>
        <time_frame>as few as 5 months, up to 16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Clomiphene Citrate</title>
            <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Letrozole</title>
            <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Complication Rate</title>
        <time_frame>September 2008 - December 2011</time_frame>
        <population>Neonatal complications reported per infant, an infant could have more than one complication.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Clomiphene Citrate</title>
            <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Letrozole</title>
            <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Complication Rate</title>
          <population>Neonatal complications reported per infant, an infant could have more than one complication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neonatal jaundice</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neonatal respiratory distress syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neonatal hospitalization &gt;3 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intrauterine growth restriction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neonatal infectin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor birth defect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congenital anomaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neonatal death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Clomiphene Citrate</title>
          <description>Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Letrozole</title>
          <description>Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Fetal Demise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Neonatal death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Mid ureteral stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Ruptured Corpus Luteum Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Heterotopic Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Pregnancy of Unknown Location</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Carcinoma of the Skin-stage 3</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="374"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="285" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>First Trimester other complication during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Post-partum Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal/pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Joint/limb pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Second Trimester Hyperemesis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Second Trimester Gestational Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Second Trimester Pre-eclampsia/ eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Second Trimester pretem labor</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Second Trimester Premature rupture of membrane</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Second Trimester Incompetant cervix</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Post-partum hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Abnormal vaginal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus complaints</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne/ oily skin</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heping Zhang</name_or_title>
      <organization>Yale University</organization>
      <phone>203-785-5185</phone>
      <email>rmn-dcc@panlists.yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

